We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-0.93%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.68B
AUM Growth
-$472M
Cap. Flow
-$289M
Cap. Flow %
-10.8%
Top 10 Hldgs %
51.96%
Holding
86
New
15
Increased
18
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$97.1M
2
DVAX
Dynavax Technologies
DVAX
+$63.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$56M
4
HRMY icon
Harmony Biosciences
HRMY
+$49.8M
5
IMVT icon
Immunovant
IMVT
+$46.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$198M
2
NTLA icon
Intellia Therapeutics
NTLA
+$102M
3
ALKS icon
Alkermes
ALKS
+$98M
4
VRNA
Verona Pharma
VRNA
+$87.5M
5
AXSM icon
Axsome Therapeutics
AXSM
+$77M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAX
26
Bicara Therapeutics
BCAX
$1.78B
$34.8M 1.3%
2,000,000
+1,203,148
+151% +$25M
AUTL
27
Autolus Therapeutics
AUTL
$397M
$33.4M 1.25%
14,218,903
-1,053,269
-7% -$3.56M
KRRO icon
28
Korro Bio
KRRO
$150M
$33.3M 1.24%
874,614
+24,614
+3% +$1.26M
TERN
29
DELISTED
Terns Pharmaceuticals
TERN
$30.9M 1.15%
5,576,558
– –
ENGN icon
30
enGene Therapeutics
ENGN
$120M
$30.3M 1.13%
4,557,575
+1,949,942
+75% +$15.1M
RARE icon
31
Ultragenyx Pharmaceutical
RARE
$2.45B
$27.5M 1.03%
+653,513
New +$32.4M
ABVX
32
Abivax
ABVX
$10.9B
$26.2M 0.98%
3,579,209
– –
CNTA
33
DELISTED
Centessa Pharmaceuticals
CNTA
$22.6M 0.84%
1,350,000
– –
BBIO icon
34
BridgeBio Pharma
BBIO
$15.7B
$22.5M 0.84%
+819,162
New +$21.2M
LKFT
35
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$21.5M 0.8%
+780,778
New +$21.8M
OLMA icon
36
Olema Pharmaceuticals
OLMA
$1B
$20.1M 0.75%
3,442,833
-557,167
-14% -$5.56M
DFTX
37
Definium Therapeutics
DFTX
$5.78B
$19.6M 0.73%
2,816,594
-4,248,505
-60% -$29.2M
EWTX icon
38
Edgewise Therapeutics
EWTX
$4.13B
$19M 0.71%
710,421
-390,115
-35% -$12.4M
BCYC
39
Bicycle Therapeutics
BCYC
$269M
$17.9M 0.67%
1,276,081
-2,271,920
-64% -$48.7M
UPB
40
Upstream Bio Inc
UPB
$343M
$16.4M 0.61%
+1,000,000
New +$22.3M
NVAX icon
41
Novavax
NVAX
$1.2B
$16.1M 0.6%
+2,000,000
New +$19.3M
IMCR icon
42
Immunocore
IMCR
$1.72B
$15.3M 0.57%
+519,376
New +$16.4M
ORKA
43
Oruka Therapeutics
ORKA
$5.82B
$14.5M 0.54%
750,000
-485,187
-39% -$11.8M
GERN icon
44
Geron
GERN
$828M
$14.2M 0.53%
4,011,287
-3,563,762
-47% -$14.2M
HELP
45
Cybin Inc
HELP
$485M
$13.5M 0.5%
1,529,987
– –
NMRA icon
46
CALL
Neumora Therapeutics
NMRA
$298M
$12.6M 0.47%
1,189,800
+1,009,300
+559% +$12.1M
XNCR icon
47
Xencor
XNCR
$1.5B
$11.5M 0.43%
500,000
-300,000
-38% -$6.89M
ALGS icon
48
Aligos Therapeutics
ALGS
$26.2M
$9.73M 0.36%
244,110
– –
RAPT
49
DELISTED
RAPT Therapeutics
RAPT
$9.5M 0.35%
+751,423
New +$9.54M
ZURA icon
50
Zura Bio
ZURA
$516M
$8.21M 0.31%
3,283,783
– –
1
2
3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Deep Track Capital held 86 positions worth $2.68B, down 15% from $3.15B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deep Track Capital withdrew a net $289M in Q4 2024, closing 23 positions and reducing 20 holdings. Its most notable exit was argenx, an estimated $198M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Harmony Biosciences worth $49.9M.

  • Deep Track Capital's largest Q4 2024 buy was Harmony Biosciences: 1,450,000 shares worth $49.9M.
  • Deep Track Capital added most to Cytokinetics in Q4 2024, an estimated $97.1M increase.
  • Deep Track Capital's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $87.5M.
  • Deep Track Capital fully exited argenx in Q4 2024, selling an estimated $198M.
  • Deep Track Capital's ten largest holdings make up 52% of its $2.68B portfolio in Q4 2024.
  • Deep Track Capital opened 15 new positions and closed 23 in Q4 2024.
  • Deep Track Capital's portfolio value fell 15% quarter-over-quarter to $2.68B.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.